{"id":"W7106485843","doi":"10.21203/rs.3.rs-8020339/v1","title":"Translational and Real-World Evidence of Trastuzumab Biosimilar CT-P6 Plus Pertuzumab in Neoadjuvant HER2-Positive Early Breast Cancer","year":2025,"lang":"","type":"preprint","venue":"Research Square","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Purdue Pharma (Canada)","funders":"","keywords":"Pertuzumab; Trastuzumab; Biosimilar; Breast cancer; Clinical endpoint; Neoadjuvant therapy; Adverse effect; Clinical trial; Biomarker","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01271501,0.0003925313,0.001072987,0.0004596709,0.0003541727,0.00254374,0.0006844925,0.001415582,0.01162548],"category_scores_gemma":[0.05771316,0.0002483099,0.001612537,0.00113421,0.001762734,0.001305783,0.0008889185,0.002306077,0.00141547],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001607266,"about_ca_system_score_gemma":0.00232927,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001089576,"about_ca_topic_score_gemma":0.0009213853,"domain_scores_codex":[0.9909615,0.006502432,0.0007970389,0.0005216561,0.0008435442,0.0003737814],"domain_scores_gemma":[0.9340291,0.0454285,0.01090248,0.003070797,0.004606798,0.001962353],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.4516164,0.004501672,0.03129289,0.03118804,0.01410342,0.0008760787,0.00137401,0.003289482,0.0120191,0.008614245,0.01914812,0.4219765],"study_design_scores_gemma":[0.1084087,0.1836963,0.2563742,0.03368103,0.0691507,0.004064371,0.005147785,0.004334703,0.01867227,0.02764261,0.2883938,0.000433732],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7542976,0.1700259,0.002307333,0.03647971,0.002073544,0.0005883835,0.006087545,0.00008718451,0.02805272],"genre_scores_gemma":[0.968334,0.02310716,0.001069059,0.003406413,0.001049063,0.0001243728,0.001937997,0.00003969235,0.000932287],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01271501,"threshold_uncertainty_score":0.06724423,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1051180978262782,"score_gpt":0.4728447306763954,"score_spread":0.3677266328501173,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}